Complex CAD Treated With PCI With DES Implantation.

Sponsor
Poznan University of Medical Sciences (Other)
Overall Status
Completed
CT.gov ID
NCT06131333
Collaborator
(none)
980
1
12
81.9

Study Details

Study Description

Brief Summary

COMPLEX Registry is an investigator-initiated, retrospective, high-volume Polish single-center clinical registry enrolling 980 consecutive patients with complex coronary artery lesions treated percutaneously between September 2015 and December 2021. All data were collected prospectively as regards the clinical and technical endpoints. The study aimed to assess the safety and efficacy of new-generation, thin-struts DES in patients with complex CAD at long-term clinical follow-up. The primary endpoint of the study was the occurrence of TLR during follow-up. Secondary endpoints were a procedural success and the occurrence of MACE, including all-cause death, MI, or TLR.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation

Study Design

Study Type:
Observational
Actual Enrollment :
980 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Complex Coronary Artery Disease Treated With Percutaneous Coronary Intervention - COMPLEX Registry.
Actual Study Start Date :
Jan 1, 2022
Actual Primary Completion Date :
Oct 30, 2022
Actual Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Complex PCI

All consecutive patients with complex coronary artery disease (CAD) were treated with percutaneous coronary intervention (PCI). The complexity of CAD was defined as having at least one of the following characteristics: chronic total occlusion (CTO), lesion length >40 mm, severe calcification assessed by angiography or intravascular imaging examination, multivessel PCI during the same intervention, or true bifurcation defined as any lesion involving both the main vessel (MV), proximal or distal and the ostium of the side branch (SB) (Medina 1,1,1; 1,0,1; or 0,1,1).

Procedure: Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation
PCI was performed according to the general and local recommendations. The choice of DES among the new generation DES and the decision on procedure optimization belonged to the operator.

Outcome Measures

Primary Outcome Measures

  1. Target lesion revascularization (TLR) [12 months]

    During the 12-month follow-up, the incidence of TLR in patients included in the study will be reported. TLR was defined as revascularization post-stenting within the stent or within the 5-mm borders adjacent to the stent.

Secondary Outcome Measures

  1. Major adverse cardiac events (MACE) [12 month]

    During the 12-month follow-up, the incidence of MACE in patients included in the study will be assessed. Major adverse cardiac event composed of all-cause death, myocardial infarction (MI), or TLR.

  2. Procedural success [Peri-procedural]

    Procedural success was defined as angiographic success in the absence of in-hospital major events including death, MI, need for TLR, stroke, vascular access site complications, and contrast agent nephropathy.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • For the inclusion of patients in this study, the complexity of CAD was defined as having at least one of the following characteristics: chronic total occlusion (CTO), lesion length >40 mm, severe calcification assessed by angiography or intravascular imaging examination, multivessel PCI during the same intervention, or true bifurcation defined as any lesion involving both the main vessel (MV), proximal or distal and the ostium of the side branch (SB) (Medina 1,1,1; 1,0,1; or 0,1,1).
Exclusion Criteria:
  • left main stem

  • PCI treated during index procedure;

  • cardiogenic shock,

  • thrombolysis before PCI;

  • 12-month follow-up not available

Contacts and Locations

Locations

Site City State Country Postal Code
1 Poznan University of Medical Sciences, Poland PoznaƄ Wielkopolska Poland 61-701

Sponsors and Collaborators

  • Poznan University of Medical Sciences

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sylwia Iwanczyk, Principal Investigator, Poznan University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT06131333
Other Study ID Numbers:
  • 821/23
First Posted:
Nov 14, 2023
Last Update Posted:
Nov 14, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 14, 2023